1	Lower Risk of Incident Cataracts and Diabetic Retinopathy amongst Individuals Treated with Sodium Glucose
2	Cotransporter-2 Inhibitor Compared to Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Mellitus
3	Li Yen Goh BMedSci BMBS FRCOphth * ^{1,2} , Oscar Hou In Chou MSc * ^{2,8} , Sharen Lee MBChB ² , Teddy Tai Loy Lee
4	BPharm ² , Jeremy Man To Hui ² , Hugo Pui Hok Him ² , Wing Tak Wong PhD ³ , Carlin Chang MPhil MRCP ⁴ , Bernard Man
5	Yung Cheung MB BChir FRCP ⁸ , Gary Tse MD PhD FRCP FFPH ^{#2, 5, 6, 7} , Jiandong Zhou PhD ^{#9,10}
6	¹ Department of Ophthalmology, King's College Hospital NHS Trust, London, United Kingdom
7	² Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China
8	³ School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China
9	⁴ Department of Medicine, Queen Mary Hospital, Hong Kong, China
10	⁵ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin
11	Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
12	⁶ Kent and Medway Medical School, Canterbury, United Kingdom
13	⁷ School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
14	⁸ Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine, The
15	University of Hong Kong, Hong Kong, China
16	⁹ Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
17	Hong Kong, China
18	¹⁰ Division of Health Sciences, Warwick Medical School, University of Warwick, United Kingdom
19	
20	*Joint first author
21	# Correspondence too: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
22	Gary Tse MD, PhD, FRCP, FFPH
23	Kent and Medway Medical School, Canterbury, United Kingdom
24	School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
25	Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University

- 26 **Tianjin 300211, China**
- 27 Email: gary.tse@kmms.ac.uk
- 28
- 29 Jiandong Zhou, PhD,
- 30 Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
- 31 Kong, China
- 32 Division of Health Sciences, Warwick Medical School, University of Warwick, United Kingdom
- 33 Email: jiandong.zhou@warwick.ac.uk

34 Synopsis/Precis

35 Sodium glucose cotransporter-2 inhibitor (SGLT2I) use was associated with lower rates of new onset diabetic

³⁶ retinopathy and cataracts compared to dipeptidyl peptidase-4 inhibitor (DPP4I) use in patients with type 2 diabetes

37 melllitus (T2DM) from Hong Kong.

38

39 What is already known on this topic

40 Various glucose lowering medications may have additional beneficial or aggravating properties for/against diabetic

41 retinopathy and cataract formation in diabetic populations beyond their glucose lowering capabilities.

42

43 What this study adds

This study showed that SGLT2I use was associated with significantly lower rates of new onset cataracts and diabetic retinopathy when compared to DPP4I use in a T2DM population in Hong Kong. Additionally, to the best of our knowledge, this is the first population-based study on the effects of SGLT2I and DPP4I use on the development of cataracts in individuals with T2DM.

48

49 How this study might affect research, practice or policy

50 This study provides preliminary data for further evaluation of SGLT2I and DPP4I use in preventing the incidence and

51 progression of cataracts and diabetic retinopathy in a T2DM individuals. This study may also aid clinicians in deciding

52 between SGLT2 and DPP4I if microvascular retinal complications and cataracts are a concern in individual cases.

53 Abstract

54 **Background/Aims**: Type 2 diabetes mellitus (T2DM) is an extremely prevalent disease with multisystem complications. 55 We aim to compare the effects of two common glucose lowering medications; sodium glucose co-transporter 2 56 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I), on the incidence of diabetic retinopathy and cataracts 57 in T2DM patients in Hong Kong.

58 **Methods**: Retrospective population-based cohort study of T2DM patients treated with SGLT2I or DPP4I between 1st 59 January 2015 and 31st December 2020. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I users was 60 performed on demographics, past co-morbidities, number of prior hospitalizations, duration from T2DM diagnosis to 61 intial drug exposure, non-SGLT2I/DPP4I medications (including other anti-diabetes drugs), abbreviated modification of 62 diet in renal disease, HbA1c, fasting glucose, and their time-weighted means. Sensitivity analysis using a one-year lag 63 time and competing risk analyses using cause-specific and sub-distribution hazard models were conducted.

Results: This study cohort included 26 165 SGLT2I and 42 796 DPP4I users (total: N=68 961 patients; 56.43% males, 64 65 median age: 62.0 years old (standard deviation (SD): 12.8)). Over a median follow-up of 5.56 years (IQR: 5.24-5.80) and after propensity score matching (SGLT2I: N=26 165; DPP4I: N=26 165), SGLT2I users had lower incidences of cataract 66 (4.54% vs. 6.64%%, standardised mean difference [SMD]=0.09) and diabetic retinopathy (3.65 vs. 6.19, SMD=0.12) 67 compared to DPP4I users. SGLT2I use was associated with lower risks of new onset cataract (HR: 0.67, 95% CI: [0.62– 68 69 0.72] P<0.0001) and diabetic retinopathy (hazard ratio [HR]: 0.57, 95% confidence interval [CI]: [0.53–0.62], P<0.0001). These associations remained significant on multivariable Cox regression ;cataract: HR: 0.69, 95% CI: 0.64–0.75 70 (P<0.0001); diabetic retinopathy: HR: 0.68, 95% CI: 0.63–0.75 (P<0.0001). 71

Conclusions: Amongst T2DM patients in Hong Kong, SGLT2I use was associated with lower risks of new onset cataract
or diabetic retinopathy compared to DPP4I use.

Keywords: Sodium-glucose co-transporter 2 inhibitors; dipeptidyl peptidase-4 inhibitors; diabetes; cataract; diabetic
retinopathy.

76 Introduction

77 Type 2 diabetes mellitus (T2DM) is a widespread disease with increasing prevalence globally. It is predicted that by 2030, up to 439 million people worldwide will have T2DM (1). The potential multi-system morbidities and mortality 78 79 associated with this disease are well documented. Cataracts and diabetic retinopathy are recognised complications, with sight threatening capabilities; both feature among the top five causes of global blindness (2). It is estimated that 80 by 2030, 191 million individuals with T2DM will have diabetic retinopathy (2). There have been several historic 81 landmark trials which have suggested that intensive blood glucose control (HbA1c <7%) achieved through medication 82 is associated with lower risks of microvascular diabetic complications (3-6). Additionally, patients with T2DM are at 83 84 higher risk of developing cataracts at an earlier age than the general population (7).

Metformin is the commonest first-line anti-diabetic agent, and if glycemic control is not optimally achieved, agents such as dipeptidyl-peptidase 4 inhibitors (DPP4I), pioglitazone and sulphonylureas or dual therapy with sodium-glucose transport protein 2 inhibitors (SGLT2I) can be prescribed. Additionally, the National Institute for Health and Care Excellence (NICE) guidance has recently advised that DPP4I or SGLT2I are among the recommended first-line treatments if metformin is contraindicated or not tolerated (8).

90

91 **Aims**

There have been arguments that various glucose lowering agents may have additional protective or aggravating properties towards ocular microvascular complications and cataract formation beyond their glucose lowering capabilities (7, 9, 10). This study aims to compare the outcomes of incident diabetic retinopathy and cataract development between SGLT2I and DPP4I users in a T2DM population in Hong Kong.

96

97 **Objectives**

To compare the outcomes of new-onset cataracts between SGLT2I and DPP4I users in a T2DM population in
Hong Kong identified through the Clinical Data Analysis and Reporting System (CDARS), a city-wide database

99	Hong Kong identified through the Clinical Data Analysis and Reporting System (CDARS), a city-wide database
100	that centralises patient information and using the International Classification of Diseases, Ninth Revision,
101	Clinical Modification (ICD-9) codes, National Centre of Health Statistics, Centers for Disease Control and
102	Prevention (11)
103	2. To compare the outcomes of new-onset diabetic retinopathy between SGLT2I and DPP4I users in a T2DM
104	population in Hong Kong identified through the CDARS, using ICD-9 codes, National Centre of Health Statistics,
105	Centers for Disease Control and Prevention (11)
106	
107	Materials and Methods
108	Study design and population
109	This study obtained ethics approval from The Joint Chinese University of Hong Kong–New Territories East Cluster
110	Clinical Research Ethics Committee and The Institutional Review Board of the University of Hong Kong/Hospital
111	Authority Hong Kong West Cluster. This was a retrospective, territory-wide cohort study of T2DM patients with SGLT2I
112	or DPP4I use between approximately 1 st January 2015 and 31 st December 2020 in Hong Kong. The patients were
113	identified via ICD-9 codes from the Clinical Data Analysis and Reporting System (CDARS), a city-wide database that
114	centralises patient information from 43 public hospitals or their associated ambulatory or outpatient facilities managed
115	by the Hong Kong Hospital Authority to establish comprehensive medical data, including clinical characteristics,
116	laboratory results, drug treatments and disease diagnosis. CDARS has been previously utilised by our team and other
117	teams in Hong Kong (12, 13). ICD-9 codes definitions were obtained from the Centers for Disease Prevention and

118 Control website (11).

119 Patients with SGLT2I or DPP4I use during the study period were identified (76 147). Excluded patients: without 120 complete demographics (N=17), under 18 years old (N=108), with prior diagnoses of cataracts, glaucoma, congenital 121 anomalies/dystrophies, rubeosis iridis, ocuar trauma/inflammation, diabetic eyes disease, retinal vascular occlusion, 122age related macular degeneration, ocular malignancy, other proliferative retinopathy or severe eye events (N = 4693), 123with prior use of setroids in the eye (N = 1 302) and those who had prebious procedure in the eyes for diabetic retinopathy diabetic macular oedema, anti-vascular endothelial growth factor injections (N = 1 066). Individuals who 124 125took medications which could cause retinopathy; anti-malarials/anti-rheumatics including, quinine, 126 hydroxychloroquine, mefloquine; anti-psychotics including phenothiazines (fluphenazine, promazine, thirodazine, 127mesoridazine), prochlorperazine, chlorpromazine, perphenazine; non-steroidal anti-inflammatory drugs, including indomethacin, antibiotics including ethambutol; heavy metal antagonists, including desferrioxamine and anti-estrogen 128129 including tamoxifen were also excluded (.

130 Clinical and biochemical data were extracted for the present study. Patient demographics include sex and age at 131commencement of initial SGLT2I/DPP4I use. Outcomes of new-onset cataracts and diabetic retinopathy were extracted 132if the condition was documented in either one or both eyes, based on ICD-9 coding. Prior co-morbidities were also 133extracted, including diabetes with chronic complications, diabetes without chronic complications, gout, heart failure, hyperlipidaemia, hypertension, hypoglycemia and hyperglycaemia (using hospitalisations as a proxy measure), 134135ischemic heart disease, liver diseases, acute myocardial infarction, peripheral vascular disease, renal diseases, 136 stroke/transient ischemic attack, VT/VF/SCD (VT: ventricular tachycardia, VF: ventricular fibrillation, SCD: sudden cardiac death), anaemia, high Body Mass Index (BMI), and cancer, based on ICD-9 codes. Charlson's standard 137138 comorbidity index was also calculated. Mortality was recorded using the International Classification of Diseases Tenth Edition (ICD-10) coding (14). 139

Medication histories were also extracted, including the use of metformin, sulphonylurea, insulin, acarbose, thiazolidinedione, glucagon-like peptide-1 receptor agonists, statins and fibrates. Baseline laboratory data, including complete blood count, biochemical tests, glycemic and lipid profiles were extracted. In addition, the abbreviated modification of diet in renal disease (AMDRD) equation was calculated to assess the renal function of the included patients (15).

145

146 *Outcomes and statistical analysis*

The study outcomes were new onset cataract and diabetic retinopathy. Mortality data were obtained from the 147Hong Kong Death Registry, a population-based official government registry with the registered death records of all 148 Hong Kong citizens linked to CDARS. The follow-up period was 31st December 2020 or until death, whichever was earlier. 149 Descriptive statistics were used to summarise the baseline, clinical and biochemical characteristics of patients with 150SGLT2I and DPP4I treatments. For baseline clinical characteristics, continuous variables were presented as median (95% 151confidence interval [CI]/ interguartile range [IQR]) or mean (standard deviation [SD]) and categorical variables were 152presented as total number (percentage). Continuous variables were compared using the two-tailed Mann-Whitney U 153test, whilst the two-tailed Chi-square test with Yates' correction was used to test 2 × 2 contingency data. 154Propensity score matching with 1:1 ratio between SGLT2I and DPP4I users based on demographics, prior co-155morbidities and hospitalisations, AMDRD, HBA1c, fasting glucose, use of different medication classes (including other 156157anti-diabetic drugs) and their time-weighted means, were performed using the nearest neighbor search strategy with the caliper as 0.1. Univariable and multivariable Cox regression models were used to identify significant risk 158predictors for the study outcomes. Competing risk analysis models (cause-specific and sub-distribution) were 159

considered with mortality outcomes. A standardised mean difference (SMD) of less than 0.2 between the treatment
groups post-weighting was considered an adequate balance. The hazard ratio (HR), 95% CI and P-value were
reported. Statistical significance is defined as P-value < 0.05. Statistical analyses were performed with RStudio
software (Version: 1.1.456) and Python (Version: 3.6). Stata software (Version 13.0) was used for propensity score
matching.

166 **Results**

167 *Basic characteristics of the study cohort*

168 This study cohort included 68 961 patients (56.43% males, median age: 62.0 years old (standard deviation (SD) 12.8) with 26 165 SGLT2I users and 42 796 DPP4I users (Figure 1). The baseline and clinical characteristics of SGLT2I and 169DPP4I users before and after 1:1 propensity score matching are shown in **Table 1**. After a median follow-up duration 170171of 5.56 years (IQR: 5.24 - 5.8), in the propensity score-matched cohort (SGLT2I: N=26 165; DPP4I: N=26 165), 2 928 172patients (5.59%) developed new onset cataract and 2 577 (4.92%) developed diabetic retinopathy (Table 2). SGLT2I 173users had lower incidences of new onset cataract, 1 190 (4.54%) vs. 1 738 (6.64%), standardized mean difference 174[SMD]=0.09 and new onset diabetic retinopathy 956 (3.65%) vs. 1 621 (6.19%), SMD=0.12), compared to DPP4I users 175(Table 2). The time to new onset cataracts was similar for both groups (Table 2), the mean time in years for SGLT2I was 1765.4 years (SD: 0.8) and 5.2 years (SD: 1.1) with a SMD of 0.21. The time to new onset diabetic diabetic retinopathy was also similar for both groups (**Table 2**), the mean time in years for SGLT2I was 5.4 years (SD: 0.8) and 5.2 years (SD: 1.1) 177with a SMD of 0.23. 178

179

180 Univariable, multivariable Cox regression models

The detailed results of univariable Cox regression in the unmatched and matched cohorts are shown in **Table 3** and 4. In the matched cohort, compared to DPP4I users, SGLT2I users showed lower risks of new onset cataract (HR: 0.67, 95% CI: [0.62–0.72] P<0.0001) and new onset diabetic retinopathy (HR: 0.57, 95% CI: [0.53–0.62], P<0.0001) (**Table 3**).

After adjustments for significant demographics, co-morbidities as listed above, length of T2 diabetes mellitus, duration 184 of usage of SGLT2I or DPP4I use, non-SGLT2I/DPP4I diabetic medications, laboratory markers (lipid and glucose markers) 185and including sensitivity analyses for chronic kidney disease stage 4 and 5, peritoneal dialysis and haemodialysis, as 186 well as previous use of insulin and glucagon-like peptide-1 receptor agonists (GLP1-RA). SGLT2I users had a statistically 187 188 significantly lower association with new onset cataract (HR: 0.76, 95% CI: [0.67–0.87 P<0.0001) and new onset diabetic retinopathy (HR:0.51, 95% CI: [0.42 – 0.61, P < 0.0001) (Table 4). This startistically significantly lower association with 189 190 new cataracts was present for common SGLT2I medications including canagliflozin and ertugliflozin, but not dapafliflozin and empagliflozin. This statistically significantly lower association with new onset diabetic retinopathy was 191 192 present for the common SGLT2I medication dapagliflozin but not canagliflozin, ertugliflozin and empagliflozin (Table 4). 193

194

195 Subgroup stratification analysis results

As expected, both SGLT2I and DPP4I user above the age of 65 had higher associations with new onset cataracts, though in both the over 65 group and in the under 65 group, DPP4I users had a stronger association that their SGLT2I counterparts in developing cataracts (**Figure 2A**). DPP4I users under the age of 65 years the highest association of new onset diabetic retinopathy than SGLT2I users of all ages and DPP4I users over the age of 65 years, SGLT2I users over the age of 65 had the lowest association (**Figure 2B**).

When stratified by sex, both males and females using DPP4I had a higher association with new onset cataracts compared to SGLT2 users and within the respective DPP4I and SGLT2I groups, females tended to have a higher association with developing cataracts (**Figure 2C**). It was found that males and females using DPP4I had a higher risk of incident diabetic retinopathy than SGLT2I users, but within the DPP4I group, males had a higher association within developing new diabetic retinopathy, whereas in the SGLT2I group women had a slightly higher association with developing new diabetic retinopathy (**Figure 2D**).

207

208 **Discussion**

This present study found that amongst patients with T2DM, SGLT2I use was statistically significantly associated with lower incidences new onset cataracts and diabetic retinopathy compared to DPP4I use. The number needed to treat was 10.08 (abosolute risk reduction (ARR) 0.099); 10.08 type 2 diabetic patients needed to be treated with SGLT2I versus DPP4I to prevent to the onset of cataracts in one patient (**Supplementary Table 1**). 7.37 (ARR 0.14) type 2 diabetic patients needed to be treated with SGLT2I versus DPP4I to prevent to the onset of diabetic retinopathy in one patient.

215 Energy derived from glucose maintains transparency in the intraocular lens. Glucose uptake is thought to be either facilitated through various glucose transporter (GLUT) channels or is sodium-dependent through members of the SGLT 216 217 family (16). In animal studies, long-term hyperglycemia therefore causes an upregulation of GLUT and the development of advanced glycation end products (16). This in turn mediates NADPH oxidation activation, triggering overproduction 218 219 of reactive oxygen species, which interrupts the normal functionining of lens fibres leading to opacification (16). 220 However, it has been observed that the SGLT2I dapagliflozin inhibits these overproductions, therefore preventing 221 cataract formation (16, 17). Correspondingly, this study found that SGLT2I users had a statistically significantly lower association with new onset cataract (HR: 0.76, 95% CI: [0.67–0.87 P<0.0001) (Table 4). This statistically significantly 222 223 lower association with new onset diabetic retinopathy was present for the common SGLT2I medication dapagliflozin but not canagliflozin, ertugliflozin and empagliflozin (Table 4), suggesting that there may be individual SGLT2I molecule 224 225 differences which provide factors protective agains cataract formation, though further randomized control trials will 226 be needed to fully establish this. SGLT2 is expressed on the renal epithelial cells lining the proximal convoluted tubule and serves to resorb glucose 227 228 and sodium from the glomerular filtrate (18). SGLT2I represses this resorption and therefore, promotes increased glycosuria as well as increased sodium and water excretion, thereby reducing blood glucose (18). The benefits of SGLT2i 229 on reducing blood glucose levels and improving cardiovascular outcomes are well-established (19, 20). However, 230 231 SGLT2I may have a direct effect on diabetic retinopathy as SGLT2 receptors are also found on retinal pericytes (18). When extracellular glucose concentrations rise, SGLT2 receptors are activated, causing an influx of glucose and sodium 232 233 (18). The overabundance of sodium causes cell swelling, contraction, and eventually pericyte loss, which is the initial 234 step in diabetic retinopathy development (18). This mechanism is supported by a study which found that the SGLTI, 235 ipragliflozin reduces diabetic retinopathy progression in diabetic Torii fatty rats, in a dose-dependent manner (17). This study which found that SGLT2I users had a statistically significantly lower association new onset diabetic retinopathy 236 (HR:0.51, 95% CI: [0.42 – 0.61, P < 0.0001) (Table 4). In the post-hoc analysis of the Empagliflozin Cardiovascular 237 238 Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial, there is no significant statistical difference in the incidence of diabetic retinopathy between empagliflozin and placebo users, which is in keeping with 239 this study in that empagliflozin does not seem to be associated with a lower risk of diabetic retinopathy compared to 240 241 DPP41. Recent studies cross-sectional studies in Taiwan and South Korean had similar findings (21, 22). Specifically, Yen et al found that empagliflozin, dapagliflozin, and canagliflozin were associated with a significantly lower risk of sight-242 threatening retinopathy than DPP-4i. This study showed that statistically significantly lower association with new onset 243

244 diabetic retinopathy was present for the common SGLT2I medication dapagliflozin but not canagliflozin, ertugliflozin and empagliflozin (**Table 4**). The differences in findings could be explained by variations in the study protocols, but also 245 246 largely due to the fact that Yen et al studies sight-threatening retinopathy and this study looks at new-onset diabetic retinopathy, therefore likely taking into account less severe forms of diabetic retinopathy as well. Dziuba et 247 248 al estimated 20-year microvascular complications in patients with T2DM and found that the addition on dapagliflozin 249 to current treatment was associated with a 9.8% decrease in incident diabetic retinopathy compared with standard 250 care (23). Therefore, recent evidence may suggest that out of all the SGLT2I medications, dapagliflozin may be 251associated better diabetic retinopathy outcomes, though further work will be needed to establish if a true protective 252effect is indeed conferred by dapagliflozin. Furthermore, other SGLT2I medications may also be beneficial for other 253diabetic complications; an anecdotal report found marked regression of diabetic macular oedema after 16 weeks of ipragliflozin (24). 254

255 DPP4I is an enzyme which is ubiquitously expressed on the surface of a variety of cells (25). It is an exopeptidase which selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors, 256 257neuropeptides, and incretin hormones, rendering them ineffective (25). DPP4I therefore function in diabetes by increasing the presence of incretin hormones including glucagon-like peptide-1 and glucose-dependent insulinotropic 258 259 polypeptide, which are major regulators of post-prandial insulin secretion, subsequently prolonging the presence of 260 insulin after food intake and supressing glucagon secretion (26). It has been postulated that DPP4I may activate the 261 stromal cell derived factor-1 alpha Src family tyrosine kinase vascular endothelial cadherin signalling pathway which 262 causes retina vascular leakage and therefore worsens diabetic retinopathy (9, 27). Additionally, the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study found diabetic retinopathy events increased by 21.4% in the 263 264 treatment group versus placebo, though this was not statistically significant (28). However, other studies suggest that 265 DPP4I does not increase the risk of diabetic retinopathy and overall blindness (29, 30). On the other hand, there are 266 other theories that DPP4I may be protective against diabetic retinopathy, supported by animal models (rats) that proposed that DPP4Is including sitagliptin, vildagliptin and may prevent breakdown of the blood retinal barrier, 267 268 inhibit the overexpression of factors including vascular endothelial growth factor and prevent retinal pericyte loss, all

of which contribute to the development and progression of diabetic retinopathy (31-33). Retrospective studies have
shown that DPP4I significantly reduced the progression of diabetic retinopathy in T2DM patients when compared to
other oral anti-diabetic medications including metformin and sulphonyureas (34, 35).

272 Currently, the effect of DPP4I on the lens beyond glycaemic control is poorly understood. To the best of our 273 knowledge, this is the first population-based study on the effects of SGLT2I and DPP4I use on the development of 274 cataract amongst patients with T2DM and our results indicate that SGLT2I is associated with lower incidence of 275 cataracts when comparent to DPP4I.

276

277 Unsurprisingly, SGLT2I and DPP4I users in older age groups (>65 years) had a higher associations with incident cataracts (Figure 2A). Within each age group (over 65 years vs under 65 years) DPP4I users of all ages had a stronger 278association than their SGLT2I counterparts in developing cataracts (Figure 2A). DPP4I users under the age of 65 had a 279280 higher risk of new onset diabetic retinopathy. DPP4I users over the ages of 65 and SGLT2I user under the age of 65 had similar sumulative incidence curves with SGLT2I users under the age of 65 ultimately having a slighing higher cumulative 281 risk from 4.5 years onwards (Figure 2B). Large cross sectional studies have determined that a younger age of onset of 282 283 diabetes being an independent risk factor for the development of diabetic retinopathy in a Chinese T2DM population, with the age of 31-45 being the highest risk group, postulating that a that the level of vascular endothelial growth factor 284 in diabetic patients is higher during an earlier age thereby promoting pathological retinal angiogenesis and 285 fibrovascular proliferation during development of diabetic retinopathy (36-39). 286

287 When stratifying by sex, both males and females using DPP4I had a higher association with new onset cataracts compared to SGLT2 users and within the respective DPP4I and SGLT2I groups, females tended to have a higher 288 289 association with developing cataracts (Figure 2C). This finding is consistent with evidence that cataracts are more common in women although the exact reason for this is uncertain (40, 41). It was also found that male and females 290 291 using DPP4I had a higher risk of incident diabetic retinopathy than SGLT2I users, but within each drug group, males had 292 a higher risk than females. Epidemiology studies have recognised that the male gender is an independent risk factor 293 for developing diabetic retinopathy (42). It was also found that males and females using DPP4I had a higher risk of incident diabetic retinopathy than SGLT2I users, but within the DPP4I group, males had a higher association within 294 295 developing new diabetic retinopathy, whereas in the SGLT2I group women had a slightly higher association with 296 developing new diabetic retinopathy (Figure 2F). Epidemiology studies which found that male sex is an independent risk factor of the development of diabetic retinopathy (Figure 2C) (42). Potential reasons for this include alterations in 297 298 ocular blood flow regulation mediated by sex hormones and inflammatory cytokine profiles variations due to sex, in 299 particular oestrogen in women having a vasodilating effect and testosterone in men having a vasoconstrictive effect potentially worsening diabetic retinopathy (42, 43). Therefore it was interesting to note in the SGLT2I group that 300 women had a higher association with new diabetic retinopathy, and possibly coule be explained by a modulating effect 301 302 of SGLT2I though much further and in depth work will need to be done to investigate this further.

303

304 Limitations

Several limitations were present in this study. First, given its observational nature, there is an inherent information bias due to under-coding, coding errors and missing data. In particular Body Mass Index (BMI) was severely undercoded and therefore unable to be adjusted for in this study. To address this, extensive laboratory results and comorbidities related to cardiovascular disease and HCC were included to infer possible risk variables indirectly. In addition, patient drug compliance could only be assessed indirectly through prescription refills. Secondly, residual and post-baseline confounding may be present despite robust propensity-matching, especially with the unavailability of information on lifestyle factors. We did try to adjust for severe hypoglycaemia and hyperglycaemia using hospitalisations (for any

reason) as a proxy measure for this but acknowledge that this is not ideal. Additionally, information on the stage of 312 313 diabetic retinopathy, progression of diabetic retinopathy, presence or absence of diabetic macular oedema, type of cataract, and complications from both ocular diseases were not available. Furthermore, surgical data for cataract and 314diabetic retinopathy were not available. Data on visual acuity was also unavailable. Hong Kong does have a diabetic 315 316 retinopathy screening programme executed by the risk assessment and management programme (RAMP) under the Hong Kong Hospital Authority, but not all patients joined this programme but those who did, would have the relevant 317 ICD codes confirmed if diagnosed with cataract or retinopathy (44). It should be emphasized that our big data approach 318 has limitations and is complementary to other research methods, such as retrospective registry review (45), cross-319 sectional recruitment from hospitals (46) or the community (47) or clinical trials (48), which have the advantages of 320 321 obtaining specific data fields that are not routinely collected.

322

323 **Conclusions**

Among T2DM patients in Hong Kong, SGLT2I use was associated with lower risks of incident cataract and new onset diabetic retinopathy compared to DPP4I use after multiple adjustment models. This study provides data for further evaluation of SGLT2I and DPP4I use in preventing the incidence and progression of cataracts and diabetic retinopathy in a T2DM individuals. This study may also aid clinicians in deciding between SGLT2 and DPP4I if microvascular complications and cataracts are a concern in individual cases.

329 Author Declarations

330 Ethics approval and consent to participate

- 331 This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong
- 332 Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and complied with the Declaration of Helsinki.

333

334 Consent for publication

335 The authors consent to the publication of manuscript.

336

337 Availability of data and materials

- 338 The data that support the findings of this study were provided by the Hong Kong Hospital Authority, but restrictions
- apply to the availability of these data, which were used under license for the current study, and so are not publicly
- available. Data are however available from the authors upon reasonable request and with permission of Hong Kong
- 341 Hospital Authority.

342

- 343 **Competing interests**
- 344 The authors declare no competing interest.

345

Funding

347 This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

348

- 349 Authors' contributions
- 350 LYG, JZ: data analysis, data interpretation, statistical analysis, manuscript drafting, critical revision of manuscript
- 351 OH, TTLL, JMHH, YHAL, CTC, WTW, CC, QPZ, SL: manuscript drafting, critical revision of manuscript
- 352 GT: study conception, study supervision, project planning, data interpretation, statistical analysis, manuscript drafting,
- 353 critical revision of manuscript
- 354
- 355 Acknowledgements
- 356 None.

357

358 Guarantor Statement

- 359 All authors approved the final version of the manuscript. GT is the guarantor of this work and, as such, had full access
- 360 to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

361

362 **References**

- 1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes Global
- Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107-11.

- 365 2. Collaborators GBaVI, Study VLEGotGBoD. Causes of blindness and vision impairment in 2020 and trends over 30
- 366 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global
- ³⁶⁷Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e60.
- 368 **3.** Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of
- 369 complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet.

1998;352(9131):837-53.

- 4. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and
- 372 Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology. 1995;102(4):647-61.
- 5. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on
- retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-44.
- 375 6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and
- vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
- 377 7. Chen YY, Wu TT, Ho CY, Yeh TC, Sun GC, Kung YH, et al. Dapagliflozin Prevents NOX- and SGLT2-Dependent
- 378 Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus. Int J Mol Sci. 2019;20(18).
- 8. NICE. Type 2 diabetes in adults: choosing medicines 2022 [cited 2022 9 March]. Available from:
- 380 <u>https://www.nice.org.uk/guidance/ng28/resources/visual-summary-full-version-choosing-medicines-for-firstline-</u>
- 381 and-further-treatment-pdf-10956472093.
- 382 9. Kim NH, Choi J, Choi KM, Baik SH, Lee J, Kim SG. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic
- retinopathy: A population-based study. Diabetes Metab. 2018;44(4):361-7.
- 10. Lahoti S, Nashawi M, Sheikh O, Massop D, Mir M, Chilton R. Sodium-glucose co-transporter 2 inhibitors and
- 385 diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab.
- **2021;10(1):3-13**.
- 11. Prevention CfDCa. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
- 388 CM) <u>https://www.cdc.gov/nchs/icd/icd10.htm2021</u> [cited 2022 26 July]. 9th Edition:[Available from:
- 389 https://www.cdc.gov/nchs/icd/icd10.htm.
- 12. Liu Y, Ling L, Wong SH, Wang MH, Fitzgerald JR, Zou X, et al. Outcomes of respiratory viral-bacterial co-infection in
- adult hospitalized patients. EClinicalMedicine. 2021;37:100955.
- 13. Zhou J, Wang X, Lee S, Wu WKK, Cheung BMY, Zhang Q, et al. Proton pump inhibitor or famotidine use and severe
- 393 COVID-19 disease: a propensity score-matched territory-wide study. Gut. 2020.
- 14. Prevention CfDCa. International Classification of Diseases, Tenth Revision (ICD-10) 2021 [cited 2022 26 July].
- 395 Available from: <u>https://www.cdc.gov/nchs/icd/icd10.htm</u>.
- 15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine
- values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern
- 398 Med. 2006;145(4):247-54.
- 16. Zhang S, Chai FY, Yan H, Guo Y, Harding JJ. Effects of N-acetylcysteine and glutathione ethyl ester drops on
- 400 streptozotocin-induced diabetic cataract in rats. Mol Vis. 2008;14:862-70.
- 401 **17**. Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of
- 402 diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci. 2016;147:125-31.
- 403 18. Wakisaka M, Kitazono T, Kato M, Nakamura U, Yoshioka M, Uchizono Y, et al. Sodium-coupled glucose transporter
- 404 as a functional glucose sensor of retinal microvascular circulation. Circ Res. 2001;88(11):1183-8.
- 405 **19.** Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, et al. Association between sodium-glucose
- 406 cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized
- 407 controlled trials. Europace. 2022;24(1):20-30.

408 20. Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, et al. Effect of sodium-glucose cotransporter-2

- inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(17):1961-73.
- 410 21. Chung YR, Ha KH, Lee K, Kim DJ. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4
- inhibitors on diabetic retinopathy and its progression: A real-world Korean study. PLoS One. 2019;14(10):e0224549.
- 412 22. Yen FS, Wei JC, Yu TS, Hung YT, Hsu CC, Hwu CM. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of
- 413 Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open. 2023;6(12):e2348431.
- 414 23. Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, et al. Modeling effects of SGLT-2 inhibitor
- 415 dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes
- 416 **Obes Metab. 2014;16(7):628-35.**
- 417 24. Yoshizumi H, Ejima T, Nagao T, Wakisaka M. Recovery from Diabetic Macular Edema in a Diabetic Patient After
- 418 Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor. Am J Case Rep. 2018;19:462-6.
- 419 25. Röhrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Front Immunol. 2015;6:386.

420 26. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr

- 421 Med Res Opin. 2007;23(4):919-31.
- 422 27. Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, et al. Dual roles of tight junction-associated protein, zonula
- 423 occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem.
- 424 **2006;281(39):29190-200**.
- 425 28. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular
- 426 Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42.
- 427 29. Hernández C, Bogdanov P, Solà-Adell C, Sampedro J, Valeri M, Genís X, et al. Topical administration of DPP-IV
- inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia. 2017;60(11):2285-98.
- 429 **30.** Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure,
- 430 hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ. 2016;352:i1450.
- 431 **31**. Dietrich N, Kolibabka M, Busch S, Bugert P, Kaiser U, Lin J, et al. The DPP4 Inhibitor Linagliptin Protects from
- 432 Experimental Diabetic Retinopathy. PLoS One. 2016;11(12):e0167853.
- 433 **32.** Maeda S, Yamagishi S, Matsui T, Nakashima S, Ojima A, Nishino Y, et al. Beneficial effects of vildagliptin on retinal
- injury in obese type 2 diabetic rats. Ophthalmic Res. 2013;50(4):221-6.
- 435 33. Gonçalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrósio AF, et al. Dipeptidyl peptidase-IV inhibition prevents
- 436 blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
- 437 Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease. 2014;1842(9):1454-63.
- 438 34. Chung YR, Park SW, Kim JW, Kim JH, Lee K. PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON
- 439 PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. Retina. 2016;36(12):2357-63.
- 440 35. Kolaczynski WM, Hankins M, Ong SH, Richter H, Clemens A, Toussi M. Microvascular Outcomes in Patients with
- 441 Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical
- 442 Records. Diabetes Ther. 2016;7(3):483-96.
- 443 36. Zou W, Ni L, Lu Q, Zou C, Zhao M, Xu X, et al. Diabetes Onset at 31–45 Years of Age is Associated with an
- Increased Risk of Diabetic Retinopathy in Type 2 Diabetes. Scientific Reports. 2016;6(1):38113.
- 445 37. Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term
- retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care. 2008;31(10):1985-90.
- 447 38. Croley AN, Zwetsloot KA, Westerkamp LM, Ryan NA, Pendergast AM, Hickner RC, et al. Lower capillarization, VEGF
- 448 protein, and VEGF mRNA response to acute exercise in the vastus lateralis muscle of aged vs. young women. J Appl
- 449 Physiol (1985). 2005;99(5):1872-9.

- 450 **39.** Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, et al. Vascular endothelial growth factor
- 451 (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and
- 452 microvascular complications. Diabet Med. 2000;17(9):650-6.
- 453 40. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study.
- 454 **Ophthalmology. 1992;99(4):546-52.**
- 455 **41**. Zhang JS, Xu L, Wang YX, You QS, Wang JD, Jonas JB. Five-year incidence of age-related cataract and cataract
- 456 surgery in the adult population of greater Beijing: the Beijing Eye Study. Ophthalmology. 2011;118(4):711-8.
- 457 42. Cherchi S, Gigante A, Spanu M, Contini P, Meloni G, Fois M, et al. Sex-Gender Differences in Diabetic Retinopathy.
- 458 International Journal of Diabetology. 2020;1:1-10.
- 459 **43**. Siddiqui MA, Khan MF, Carline TE. Gender differences in living with diabetes mellitus. Mater Sociomed.
- 460 **2013;25(2):140-2**.
- 461 44. Lian JX, Gangwani RA, McGhee SM, Chan CK, Lam CL, Wong DS, et al. Systematic screening for diabetic
- retinopathy (DR) in Hong Kong: prevalence of DR and visual impairment among diabetic population. Br J Ophthalmol.
- 463 **2016;100(2):151-5**.
- 464 45. Tse G, Zhou J, Woo SWD, Ko CH, Lai RWC, Liu T, et al. Multi-modality machine learning approach for risk
- stratification in heart failure with left ventricular ejection fraction </= 45. ESC Heart Fail. 2020.
- 466 46. Lui MM, Mak JC, Lai AY, Hui CK, Lam JC, Lam DC, et al. The Impact of Obstructive Sleep Apnea and Tobacco
- 467 Smoking on Endothelial Function. Respiration. 2016;91(2):124-31.
- 468 47. Ip MS, Lam WK, Lai AY, Ko FW, Lau AC, Ling SO, et al. Reference values of diffusing capacity of non-smoking
- 469 Chinese in Hong Kong. Respirology. 2007;12(4):599-606.
- 470 48. Lai AY, Fong DY, Lam JC, Weaver TE, Ip MS. Linguistic and psychometric validation of the Chinese version of the
- 471 self-efficacy measures for sleep apnea questionnaire. Sleep Med. 2013;14(11):1192-8.

472



Figure 1. Flowchart of data processing.

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.



Cumulative incidence curve by drug use after propensity score matching



Figure 2. Age-drug specific cumulative incidence curves of new onset cataract and new onset diabetic retinopathy in the matched cohort (1:1)

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.





Figure 3. Sex-drug specific cumulative incidence curves of new onset cataract and new onset diabetic retinopathy in the matched cohort (1:1)

SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.

Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

* for SMD \geq 0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; SD: standard deviation; CV: Coefficient of variation; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching				After matching			
Characteristics	All (N=68961) Mean(SD);N or Count(%)	SGLT2I (N=26165) Mean(SD);N or Count(%)	DPP4I (N=42796) Mean(SD);N or Count(%)	SM D	All (N=52330) Mean(SD);N or Count(%)	SGLT2I (N=26165) Mean(SD);N or Count(%)	DPP4I (N=26165) Mean(SD);N or Count(%)	SM D
Demographics								
Male gender	38919(56.43%)	15809(60.42%)	23110(54.00%)	0.1 3	31603(60.39%)	15809(60.42%)	15794(60.36%)	<0. 01
Female gender	30042(43.56%)	10356(39.57%)	19686(45.99%)	0.1 3	20727(39.60%)	10356(39.57%)	10371(39.63%)	<0. 01
Baseline age, years	62.0(12.8)	57.6(11.4	64.7(12.9)	0.5 8*	58.4(11.2);n=523 30	57.6(11.4);n=261 65	59.2(10.9);n=261 65	0.1 5
18-50	10963(15.89%)	5856(22.38%)	5107(11.93%)	0.2 8*	10277(19.63%)	5856(22.38%)	4421(16.89%)	0.1 4
50-60	20149(29.21%)	9374(35.82%)	10775(25.17%)	0.2 3*	19142(36.57%)	9374(35.82%)	9768(37.33%)	0.0 3
60-70	19949(28.92%)	7628(29.15%)	12321(28.79%)	0.0 1	15743(30.08%)	7628(29.15%)	8115(31.01%)	0.0 4
70-80	11326(16.42%)	2656(10.15%)	8670(20.25%)	0.2 8*	5660(10.81%)	2656(10.15%)	3004(11.48%)	0.0 4
>80	6584(9.54%)	658(2.51%)	5926(13.84%)	0.4 2*	1515(2.89%)	658(2.51%)	857(3.27%)	0.0 5
Financial aid	2299(3.33%)	988(3.77%)	1311(3.06%)	0.0 4	1913(3.65%)	988(3.77%)	925(3.53%)	0.0 1
Past comorbidities								
Charlson's standard comorbidity index	2.0(1.5)	1.5(1.2)	2.2(1.5)	0.5 1*	1.6(1.2);n=52330	1.5(1.2);n=26165	1.6(1.2);n=26165	0.1
Duration from earliest diabetes mellitus diagnosis date to baseline date, day	6.5(5.0)	6.47(4.93)	6.47(5.05)	<0. 01	6.4(4.8);n=52330	6.5(4.9);n=26165	6.2(4.6);n=26165	0.0 5
Number of hospitalizations	1.2(0.8)	1.3(1.1)	1.2(0.6)	0.1 7	1.3(0.9);n=52330	1.3(1.1);n=26165	1.2(0.8);n=26165	0.1 3

Diabetes with chronic complication	259(0.37%)	82(0.31%)	177(0.41%)	0.0 2	164(0.31%)	82(0.31%)	82(0.31%)	<0. 01
Diabetes without chronic complication	1154(1.67%)	507(1.93%)	647(1.51%)	0.0 3	1000(1.91%)	507(1.93%)	493(1.88%)	<0. 01
Hyperlipidaemia	49328(71.53%)	19558(74.74%)	29770(69.56%)	0.1 2	39243(74.99%)	19558(74.74%)	19685(75.23%)	0.0 1
Hypertension	40033(58.05%)	19111(73.04%)	20922(48.88%)	0.5 1*	36271(69.31%)	19111(73.04%)	17160(65.58%)	0.1 6
Hypoglycemia	434(0.62%)	73(0.27%)	361(0.84%)	0.0 8	146(0.27%)	73(0.27%)	73(0.27%)	<0. 01
Autoimmune disease tissue	695(1.00%)	257(0.98%)	438(1.02%)	<0. 01	512(0.97%)	257(0.98%)	255(0.97%)	<0. 01
Heart failure	2011(2.91%)	642(2.45%)	1369(3.19%)	0.0 4	1272(2.43%)	642(2.45%)	630(2.40%)	<0. 01
Acute myocardial infarction	1844(2.67%)	856(3.27%)	988(2.30%)	0.0 6	1693(3.23%)	856(3.27%)	837(3.19%)	<0. 01
Atrial fibrillation	1679(2.43%)	570(2.17%)	1109(2.59%)	0.0 3	1134(2.16%)	570(2.17%)	564(2.15%)	<0. 01
Stroke/transient ischemic attack	1931(2.80%)	608(2.32%)	1323(3.09%)	0.0 5	1208(2.30%)	608(2.32%)	600(2.29%)	<0. 01
Ischemic heart disease	6688(9.69%)	3174(12.13%)	3514(8.21%)	0.1 3	6022(11.50%)	3174(12.13%)	2848(10.88%)	0.0 4
Peripheral vascular disease	359(0.52%)	101(0.38%)	258(0.60%)	0.0 3	202(0.38%)	101(0.38%)	101(0.38%)	<0. 01
Anemia	2426(3.51%)	578(2.20%)	1848(4.31%)	0.1 2	1141(2.18%)	578(2.20%)	563(2.15%)	<0. 01
Liver diseases	2680(3.88%)	1206(4.60%)	1474(3.44%)	0.0 6	2330(4.45%)	1206(4.60%)	1124(4.29%)	0.0 2
Renal diseases	4324(6.27%)	1035(3.95%)	3289(7.68%)	0.1 6	2049(3.91%)	1035(3.95%)	1014(3.87%)	<0. 01
Gout	1870(2.71%)	585(2.23%)	1285(3.00%)	0.0 5	1162(2.22%)	585(2.23%)	577(2.20%)	<0. 01
Cancer	1755(2.54%)	515(1.96%)	1240(2.89%)	0.0 6	1028(1.96%)	515(1.96%)	513(1.96%)	<0. 01
Overweight, obesity and hyperalimentation	675(0.97%)	278(1.06%)	397(0.92%)	0.0 1	627(1.19%)	278(1.06%)	349(1.33%)	0.0 2

Drug abuse	1117(1.61%)	180(0.68%)	937(2.18%)	0.1 3	359(0.68%)	180(0.68%)	179(0.68%)	<0. 01
Medications								
SGLT2I v.s. DPP4I	26165(37.94%)	26165(100.00%)	0(0.00%)	inf*	26165(50.00%)	26165(100.00%)	0(0.00%)	inf*
SGLT2I frequency	-	7.1(9.4)	-	-	-	7.1(9.4)	-	-
DPP4I frequency	-	-	5.5(7.5)	-	-	-	5.8(7.0)	-
SGLT2I duration, days	-	501.4(624.4)	-	-	-	501.4(624.4)	-	-
DPP4I duration, days	-	-	521.8(301.3)	-	-	-	544.2(320.3)	-
Number of anti-diabetic drug classes	4.4(0.9)	4.5(1.0);	4.4(0.8)	0.1 7	4.5(0.9)	4.51(0.96)	4.54(0.9)	0.0 3
Metformin	62207(90.20%)	24372(93.14%)	37835(88.40%)	0.1 6	48821(93.29%)	24372(93.14%)	24449(93.44%)	0.0 1
Sulphonylurea	44457(64.46%)	19118(73.06%)	25339(59.20%)	0.3 0*	37909(72.44%)	19118(73.06%)	18791(71.81%)	0.0 3
Insulin	33417(48.45%)	12806(48.94%)	20611(48.16%)	0.0 2	25608(48.93%)	12806(48.94%)	12802(48.92%)	<0. 01
Acarbose	2141(3.10%)	961(3.67%)	1180(2.75%)	0.0 5	1887(3.60%)	961(3.67%)	926(3.53%)	0.0 1
Thiozolidinedone	13513(19.59%)	6889(26.32%)	6624(15.47%)	0.2 7*	12972(24.78%)	6889(26.32%)	6083(23.24%)	0.0 7
Glucagon-like peptide-1 receptor agonists	3234(4.68%)	1578(6.03%)	1656(3.86%)	0.1	2917(5.57%)	1578(6.03%)	1339(5.11%)	0.0 4
ACEI/ARB	24467(35.47%)	9417(35.99%)	15050(35.16%)	0.0 2	17904(34.21%)	9417(35.99%)	8487(32.43%)	0.0 7
Antibiotics	45870(66.51%)	16933(64.71%)	28937(67.61%)	0.0 6	34407(65.75%)	16933(64.71%)	17474(66.78%)	0.0 4
Aspirin	13916(20.17%)	5311(20.29%)	8605(20.10%)	<0. 01	10697(20.44%)	5311(20.29%)	5386(20.58%)	0.0 1
Anticoagulants	18640(27.02%)	7250(27.70%)	11390(26.61%)	0.0 2	14853(28.38%)	7250(27.70%)	7603(29.05%)	0.0 3
Antiplatelets	17222(24.97%)	6226(23.79%)	10996(25.69%)	0.0 4	11987(22.90%)	6226(23.79%)	5761(22.01%)	0.0 4
Lipid-lowering drugs	28876(41.87%)	11346(43.36%)	17530(40.96%)	0.0 5	23454(44.81%)	11346(43.36%)	12108(46.27%)	0.0 6
Statins and fibrates	37249(54.01%)	16484(63.00%)	20765(48.52%)	0.2 9*	31793(60.75%)	16484(63.00%)	15309(58.50%)	0.0 9

Diuretics	31618(45.84%)	10291(39.33%)	21327(49.83%)	0.2 1*	21064(40.25%)	10291(39.33%)	10773(41.17%)	0.0 4
Alpha-blockers	8162(11.83%)	2774(10.60%)	5388(12.58%)	0.0 6	5116(9.77%)	2774(10.60%)	2342(8.95%)	0.0 6
Beta-blockers	16127(23.38%)	6690(25.56%)	9437(22.05%)	0.0 8	11327(21.64%)	6690(25.56%)	4637(17.72%)	0.1 9
Calcium channel blockers	12538(18.18%)	5216(19.93%)	7322(17.10%)	0.0 7	9409(17.98%)	5216(19.93%)	4193(16.02%)	0.1
Anti-cancer drugs	2319(3.36%)	515(1.96%)	1804(4.21%)	0.1 3	1033(1.97%)	515(1.96%)	518(1.97%)	<0. 01
Antipsychotics	3290(4.77%)	1082(4.13%)	2208(5.15%)	0.0 5	2123(4.05%)	1082(4.13%)	1041(3.97%)	0.0 1
Non-steroidal anti-inflammatory drugs	14046(20.36%)	5637(21.54%)	8409(19.64%)	0.0 5	11072(21.15%)	5637(21.54%)	5435(20.77%)	0.0 2
Antimalarials/Anti-rheumatics	18(0.02%)	9(0.03%)	9(0.02%)	0.0 1	18(0.03%)	9(0.03%)	9(0.03%)	<0. 01
Antiestrogen	1092(1.58%)	395(1.50%)	697(1.62%)	0.0 1	788(1.50%)	395(1.50%)	393(1.50%)	<0. 01
Calculated biomarkers				_				
Abbreviated MDRD, mL/min/1.73m^2	88.3(27.2);n=563 70	90.5(24.0);n=216 76	87.0(28.9);n=346 94	0.1 3	92.1(25.3);n=436 19	90.5(24.0);n=216 76	93.7(26.4);n=219 43	0.1 3
Kidney failure (<15)	90.0(0.13%)	14.0(0.05%)	76.0(0.17%)	0.0 4	24.0(0.04%)	14.0(0.05%)	10.0(0.03%)	0.0 1
Severe dysfunction (15-30)	644.0(0.93%)	66.0(0.25%)	578.0(1.35%)	0.1 2	138.0(0.26%)	66.0(0.25%)	72.0(0.27%)	<0. 01
Moderate dysfunction (30-60)	7722.0(11.19%)	1804.0(6.89%)	5918.0(13.82%)	0.2 3*	4149.0(7.92%)	1804.0(6.89%)	2345.0(8.96%)	0.0 8
Mild renal dysfunction (60-90)	20964.0(30.39%)	9245.0(35.33%)	11719.0(27.38%)	0.1 7	16444.0(31.42%)	9245.0(35.33%)	7199.0(27.51%)	0.1 7
Kidney damage with normal GFR (>90)	26950.0(39.08%)	10547.0(40.30%)	16403.0(38.32%)	0.0 4	22864.0(43.69%)	10547.0(40.30%)	12317.0(47.07%)	0.1 4
Neutrophil-to-lymphocyte ratio	3.5(4.6);n=28169	3.0(3.8);n=11569	3.8(5.1);n=16600	0.1 8	3.2(3.9);n=22245	3.0(3.8);n=11569	3.3(4.0);n=10676	0.0 9
Platelet-to-lymphocyte ratio	142.6(149.0);n=2 8168	132.7(153.9);n=1 1568	149.5(145.1);n=1 6600	0.1 1	135.2(138.5);n=2 2244	132.7(153.9);n=1 1568	137.9(119.5);n=1 0676	0.0 4

Triglyceride-glucose index	7.6(0.7);n=47474	7.7(0.7);n=18820	7.5(0.7);n=28654	0.1 6	7.6(0.7);n=37778	7.7(0.7);n=18820	7.6(0.7);n=18958	0.0 2
Complete blood counts				-				
Mean corpuscular volume, fL	87.2(7.5);n=3488 3	86.8(7.1);n=1459 5	87.5(7.7);n=2028 8	0.1	86.9(7.2);n=2753 8	86.8(7.1);n=1459 5	87.1(7.3);n=1294 3	0.0 5
Eosinophil, x10^9/L	0.2(0.2);n=28148	0.22(0.2);n=1156 6	0.22(0.27);n=165 82	<0. 01	0.2(0.2);n=22241	0.22(0.2);n=1156 6	0.21(0.21);n=106 75	<0. 01
Lymphocyte, x10^9/L	2.0(0.9);n=28173	2.2(0.9);n=11571	1.9(0.9);n=16602	0.2 5*	2.1(0.9);n=22248	2.2(0.9);n=11571	2.1(0.8);n=10677	0.0 9
Neutrophil, x10^9/L	5.3(2.8);n=28173	5.2(2.5);n=11571	5.4(3.0);n=16602	0.1	5.2(2.6);n=22248	5.2(2.5);n=11571	5.3(2.8);n=10677	0.0 7
White cell count, x10^9/L	8.0(3.0);n=34895	7.98(2.67);n=146 02	8.03(3.17);n=202 93	0.0 2	8.0(2.7);n=27546	8.0(2.7);n=14602	8.1(2.8);n=12944	0.0 3
Mean cell haemoglobin, pg	29.4(3.0);n=3488 3	29.2(2.9);n=1459 5	29.6(3.1);n=2028 8	0.1 1	29.3(2.9);n=2753 8	29.2(2.9);n=1459 5	29.4(2.9);n=1294 3	0.0 6
Platelet, x10^9/L	239.7(71.6);n=34 892	243.6(67.7);n=14 600	236.9(74.2);n=20 292	0.0 9	243.4(69.2);n=27 543	243.6(67.7);n=14 600	243.2(70.8);n=12 943	0.0 1
Red cell count, x10^12/L	4.6(0.7);n=34883	4.8(0.6);n=14595	4.4(0.7);n=20288	0.4 8*	4.7(0.6);n=27538	4.8(0.6);n=14595	4.6(0.6);n=12943	0.1 7
Liver and renal functions								
Potassium, mmol/L	4.3(0.5);n=56184	4.3(0.43);n=2162 5	4.35(0.49);n=345 59	0.1 2	4.3(0.5);n=43500	4.3(0.43);n=2162 5	4.32(0.47);n=218 75	0.0 4
Albumin, g/L	41.8(3.9);n=4356 1	42.6(3.3);n=1826 9	41.3(4.2);n=2529 2	0.3 3*	42.4(3.6);n=3511 3	42.6(3.3);n=1826 9	42.1(3.9);n=1684 4	0.1 2
Sodium, mmol/L	139.3(2.9);n=562 12	139.2(2.7);n=216 30	139.3(3.0);n=345 82	0.0 4	139.2(2.8);n=435 29	139.2(2.7);n=216 30	139.3(2.9);n=218 99	0.0 4
Urea, mmol/L	6.3(3.2);n=56205	5.7(2.0);n=21628	6.8(3.7);n=34577	0.3 7*	5.9(2.3);n=43533	5.7(2.0);n=21628	6.1(2.5);n=21905	0.1 7
Protein, g/L	74.0(5.4);n=4092 4	74.4(5.0);n=1721 4	73.6(5.7);n=2371 0	0.1 4	74.3(5.2);n=3292 7	74.4(5.0);n=1721 4	74.2(5.5);n=1571 3	0.0 5
Creatinine, umol/L	90.8(64.3);n=563 70	78.5(26.5);n=216 76	98.4(78.3);n=346 94	0.3 4*	82.8(37.3);n=436 19	78.5(26.5);n=216 76	87.0(45.1);n=219 43	0.2 3*
Alkaline phosphatase, U/L	76.9(31.8);n=436 84	74.4(26.1);n=182 77	78.8(35.1);n=254 07	0.1 4	76.0(30.1);n=352 14	74.4(26.1);n=182 77	77.8(33.7);n=169 37	0.1 1
Aspartate transaminase, U/L	28.5(38.9);n=172 28	29.0(29.2);n=731 5	28.2(44.7);n=991 3	0.0 2	29.3(32.0);n=141 47	29.0(29.2);n=731 5	29.6(34.8);n=683 2	0.0 2

Alanine transaminase 11/1	29.9(32.3);n=372	32.8(29.1);n=155	27.9(34.2);n=216	0.1	32.3(29.2);n=292	32.8(29.1);n=155	31.8(29.4);n=137	0.0
Alarinie transaminase, 0/L	28	42	86	6	64	42	22	4
Bilirubin umol/I	11.4(7.0);n=4348	11.5(6.2);n=1823	11.3(7.5);n=2524	0.0	11.5(6.8);n=3505	11.5(6.2);n=1823	11.4(7.5);n=1681	0.0
	4	9	5	3	4	9	5	3
Lipid profiles and variabilities								
Trightcorido mmol/I	1 9/1 6).0-52072	1.9(1.9)	1 7/1 Elin-2000	0.0	1.0(1.7), -11601	1.84(1.84);n=207	1.82(1.6);n=2094	0.0
There is a second	1.8(1.0);11=52972	1.8(1.8);11=20733	1.7(1.5);11=32239	8	1.8(1.7);1=41081	33	8	1
SD of trightcorido	0 E/1 1):0-27700	0.52(1.17);n=128	0.48(0.96);n=148	0.0	0 E(1 2) = 22709	0.52(1.17);n=128	0.54(1.15);n=109	0.0
SD OF trigiyceride	0.5(1.1),11-27700	11	89	4	0.5(1.2),11-25798	11	87	2
Time weighted mean of triglyceride,	1.9(1.0) = -24409	1.0(1.0) m = 1 E 4 7 E	1.0(1.0) -10022	0.0	1.0(1.1) $n = 20074$	1.87(1.01);n=154	1.91(1.17);n=133	0.0
mmol/L	1.0(1.0),11-34408	1.9(1.0),11-13475	1.0(1.0),11-10555	5	1.9(1.1),11-20074	75	99	4
low-density lineprotein mmol/l	2 1/0 8)·n-51070	$2/(0.8) \cdot n - 20328$	$2 1(0 8) \cdot n - 31651$	<0.	$2.4(0.8)\cdot n = 40705$	$2/1(0.8) \cdot n - 20328$	2.42(0.81);n=203	0.0
	2.4(0.8),11-51575	2.4(0.8),11-20328	2.4(0.8),11-31031	01	2.4(0.8),11-40705	2.4(0.8),11-20328	77	3
SD of low-density linoprotein	0.4(0.3) m = 26815	$0.2(0.2) \cdot n - 12/17$	0.4(0.4) m = 1.4308	0.1	$0.4(0.3) \cdot n - 22033$	$0.2(0.2) \cdot n - 12/17$	0.4(0.3) m = 10516	0.0
SD of low-density inpoprotein	0.4(0.5),11=20015	0.5(0.5),11-12417	0.4(0.4),11-14550	1	0.4(0.3),11-22333	0.5(0.5),11-12417	0.4(0.3),11-10510	7
Time weighted mean of low-density	2 3(0 6)·n-32155	2.31(0.57);n=144	2.34(0.59);n=177	0.0	$23(0.6)\cdot n - 27077$	2.31(0.57);n=144	2.29(0.61);n=126	0.0
lipoprotein, mmol/L	2.5(0.0),11-52155	00	55	7	2.5(0.0),11-27077	00	77	3
High-density linoprotein mmol/l	1 2/0 3)·n-52888	1.16(0.31);n=206	1.21(0.34);n=321	0.1	$1.2(0.3) \cdot n - 11576$	1.16(0.31);n=206	1.18(0.34);n=208	0.0
	1.2(0.5),11=52000	95	93	4	1.2(0.3),11-41370	95	81	4
SD of high-density linoprotein	0 1/0 1)·n=26618	0.09(0.08);n=122	0.11(0.09);n=143	0.1	$0.1(0.1)\cdot n=22821$	0.09(0.08);n=122	0.1(0.09);n=1053	0.0
bb of high density ipoprotein	0.1(0.1),11-20010	83	35	4	0.1(0.1),11-22021	83	8	6
Time weighted mean of high-density	1 2(0 2)·n=33930	1.16(0.19);n=153	1.18(0.21);n=185	0.0	1 2(0 2)·n=28648	1.16(0.19);n=153	1.16(0.21);n=132	0.0
lipoprotein, mmol/L	1.2(0.2),11-33330	52	78	8	1.2(0.2),11-20040	52	96	2
Total cholesterol mmol/l	4 4(1 0)·n=53023	4 4(1 0)·n=20756	4 3(1 0)·n=32267	<0.	4 4(1 0)·n=41737	4.35(1.02);n=207	4.38(0.99);n=209	0.0
	4.4(1.0),11-33023	4.4(1.0),11-20750	4.5(1.0),11-52207	01	4.4(1.0),11-41/3/	56	81	3
SD of total cholesterol	0 4(0 4)·n=27725	0 4(0 4)·n=12810	0 5(0 4)·n=14915	0.0	0 4(0 5)·n=23768	0 4(0 4)·n=12810	0 5(0 5)·n=10958	0.0
	0.1(0.1))	0(0)) ==0=0	0.0(01.1)).1 2.020	9				8
Time weighted mean of total	4.3(0.6):n=34444	4.3(0.6):n=15502	4.4(0.6):n=18942	0.0	4.3(0.6):n=28918	4.31(0.61);n=155	4.34(0.66);n=134	0.0
cholesterol, mmol/L				8		02	16	5
Glucose profiles and variabilities								
Hemoglobin A1C, %	8.1(1.5);n=55189	8.2(1.6);n=21276	7.9(1.5);n=33913	0.2	8.2(1.6);n=42918	8.2(1.6);n=21276	8.1(1.6);n=21642	0.1
SD of homeolopin A1C	0 (0 7)	0.56(0.75);n=167	0.57(0.71);n=223	0.0	0.0(0.7) m $- 21000$	0.56(0.75);n=167	0.57(0.68);n=152	0.0
	0.0(0.7);11=39096	73	23	1	0.0(0.7);n=31986	73	13	1
Time weighted mean of HhA1C %	7 8/1 1).n-10010	$7 \Omega(1 A) = 17596$	7 9(1 1)·n-22251	0.0	7 Q(1 1) m-22206	$7 \Omega(1 A) = 17596$	7 9(1 E)·n-15700	0.0
Time weighted meall OF DDATC, 70	7.0(1.4),11-40040	/.5(1.4),11-1/380	1.0(1.4),11-23234	6	7.3(1.4),11-33260	/.5(1.4),11-1/360	1.0(1.3),11-13700	3

Easting glucose mmol/L 1	Q 0/3 8)·n-50051	9 2(2 6)·n=19579	$88(30) \cdot n - 30/72$	01	0 2/2 8)·n-20/22	$9.2(3.6) \cdot n - 19579$	$9.1(1.0) \cdot n - 108/1$	0.0
	9.0(3.8),11-50051	9.2(3.0),11-19579	0.0(5.9),11-50472	0.1	9.2(3.8),11-39423	9.2(3.0),11-19579	9.1(4.0),11-19844	1
SD of fasting glucose	1 0/2 2)·n-21/12	1 8/1 0)·n-1/172	$21(24) \cdot n - 17240$	0.1	$1.0(2.0) \cdot n - 26258$	$1.8(1.0) \cdot n - 1/172$	$20(22) \cdot n - 12086$	0.0
SD OF fasting glucose	1.9(2.2),11-51412	1.0(1.9),11-14172	2.1(2.4),11-17240	2	1.9(2.0),11-20238	1.0(1.9),11-14172	2.0(2.2),11-12080	8
Time weighted mean of fasting glucose,	7 8/2 010-27620	70(20) -16425	7 9/2 0\.n-2110E	0.0	70/20) $m = 21114$	70(20) $n = 1642E$	9.0(2.0) $m = 1.4690$	0.0
mmol/L	7.8(3.0);11=37620	7.9(2.9),11=10425	7.0(5.0),11=21195	3	7.9(3.0),11=31114	7.9(2.9),11=10425	0.0(5.0),11=14089	5

	Before matching			After matching				
Characteristics	All (N=68961) Mean(SD); N or Count(%)	SGLT2I (N=26165) Mean(SD);N or Count(%)	DPP4I (N=42796) Mean(SD); N or Count(%)	SM D	All (N=52330) Mean(SD);N or Count(%)	SGLT2I (N=26165) Mean(SD); N or Count(%)	DPP4I (N=26165) Mean(SD); N or Count(%)	SM D
All-cause mortality	6388(9.26%)	727(2.77%)	5661(13.22%)	0.3 9*	2825(5.39%)	727(2.77%)	2098(8.01%)	0.2 3*
Time to mortality, years	5.4(0.7)	5.5(0.4)	5.3(0.9)	0.3 8*	5.5(0.6)	5.5(0.4)	5.4(0.7)	0.2 6*
Cardiovascular mortality	1932(2.80%)	148(0.56%)	1784(4.16%)	0.2 4*	647(1.23%)	148(0.56%)	499(1.90%)	0.1 2
Time to CAD mortality, years	5.4(0.7)	5.5(0.4)	5.3(0.9)	0.3 8*	5.5(0.6)	5.5(0.4)	5.4(0.7)	0.2 6*
New onset cataract	5104(7.40%)	1190(4.54%)	3914(9.14%)	0.1 8	2928 (5.59%)	1190 (4.54%)	1738 (6.64%)	0.0 9
Time to cataract, year	5.1(1.2)	5.4(0.8)	5.0(1.3)	0.3 6*	5.3(1.0)	5.4(0.8)	5.2(1.1)	0.2 1*
New onset diabetic retinopathy	3085(4.47%)	956(3.65%)	2129(4.97%)	0.0 7	2577(4.92%)	956(3.65%)	1621(6.19%)	0.1 2
Time to Diabetic retinopathy, year	5.2(1.0)	5.4(0.8)	5.1(1.1)	0.3 *	5.3(1.0)	5.4(0.8)	5.2(1.1)	0.2 3*

Table 2. Outcome characteristics in patients by SGLT2I v.s. DPP4I use before and after propensity score matching (1:1). * for SMD≥0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.

Table 3. Univariate Cox regression models in the match cohort.

* for SMD≥0.1; HR: hazard ratio; CI: confidence interval; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.

	New onset cataract HR [95% Cl];P value	New onset diabetic retinopathy HR [95% CI];P value
SGLT2I v.s. DPP4I	0.67[0.62-0.72];<0.0001***	0.57[0.53-0.62];<0.0001***
Dapagliflozin v.s. DPP4I	0.77[0.71-0.84];<0.0001***	0.63[0.57-0.69];<0.0001***
Empagliflozin v.s. DPP4I	0.76[0.67-0.87];<0.0001***	0.73[0.64-0.84];<0.0001***
Canagliflozin v.s. DPP4I	0.68[0.60-0.78];<0.0001***	0.72[0.63-0.83];<0.0001***
Ertugliflozin v.s. DPP4I	0.68[0.56-0.82];<0.0001***	0.69[0.56-0.84];0.0002***

Table 4. Cox univariate sensitivity analysis with exclusion of patient's chronic kidney disease stage 4 or 5 (eGFR <30), peritoneal dialysis or haemodialysis and patients who used insulin and/or GLP-1 RA in the matched cohort

* for $p \le 0.05$, ** for $p \le 0.01$, *** for $p \le 0.001$; HR: hazard ratio; CI: confidence interval; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor.

	New onset cataract HR [95% CI]; P value	New onset diabetic retinopathy HR [95% CI]; P value
SGLT2I v.s. DPP4I	0.76[0.67-0.87];<0.0001***	0.51[0.42-0.61];<0.0001***
Dapagliflozin v.s. DPP4I	0.95[0.82-1.10];0.4824	0.54[0.42-0.68];<0.0001***
Empagliflozin v.s. DPP4I	0.75[0.60-0.95];0.0149	0.65[0.47-0.91];0.0127*
Canagliflozin v.s. DPP4I	0.64[0.51-0.81];0.0002***	0.71[0.52-0.98];0.0372*
Ertugliflozin v.s. DPP4I	0.61[0.43-0.87];0.0060**	0.54[0.32-0.90];0.0192*